Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
227.43
-0.50 (-0.22%)
Feb 21, 2025, 4:00 PM EST - Market closed
BDX Revenue
Becton, Dickinson and Company had revenue of $5.17B in the quarter ending December 31, 2024, with 9.82% growth. This brings the company's revenue in the last twelve months to $20.64B, up 5.89% year-over-year. In the fiscal year ending September 30, 2024, Becton, Dickinson and Company had annual revenue of $20.18B with 4.16% growth.
Revenue (ttm)
$20.64B
Revenue Growth
+5.89%
P/S Ratio
3.19
Revenue / Employee
$282,740
Employees
73,000
Market Cap
65.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BDX News
- 8 days ago - BD to Present at Investor Healthcare Conferences - PRNewsWire
- 13 days ago - Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit - CNBC
- 15 days ago - Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business - Benzinga
- 16 days ago - Becton Dickinson looks to separate life sciences unit - Reuters
- 16 days ago - BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value - PRNewsWire
- 16 days ago - BD Reports First Quarter Fiscal 2025 Financial Results - PRNewsWire
- 18 days ago - Starboard Value pushes Becton Dickinson to sell life sciences unit, FT reports - Reuters